Business
Bioasis Appoints Dr. Deborah Rathjen as President & Chief Executive Officer
Bioasis Appoints Dr. Deborah Rathjen as President & Chief Executive Officer.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\n \n BIOASIS \n TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, \n research-stage biopharmaceutical company developing its proprietary xB3 \n TM platform technology for the delivery of therapeutics across the \n blood-brain barrier (BBB) and the treatment of CNS disorders in areas of \n high unmet medical need, including brain cancers and neurodegenerative \n diseases, today announced that its board of directors has appointed Dr. \n Deborah A. Rathjen as president and chief executive officer. Dr. \n Rathjen, who is a member of the board of directors and has served as \n executive chair since December 10, 2018, replaces Dr. Mark Day, who has \n left the company, effective immediately.\n \n \n “Deborah has significant experience in company building and financing, \n mergers and acquisitions, therapeutic product research and development, \n business development, licensing and commercialization,” said David M. \n Wurzer, lead independent director. “Her skills and track record, \n combined with her recent experience working closely with Bioasis \n management in her capacity as executive chair, put her in a strong \n position to assume leadership of company. I am delighted that Deborah \n has agreed to become our new CEO and look forward to continuing to work \n with her in this new role.”\n \n \n “I am excited to assume leadership of Bioasis at this important time in \n the company’s development” said Dr. Rathjen. “We have made important \n strides in advancing the xB3 TM platform recently and I am \n looking forward to applying my expertise in CNS, oncology clinical \n development and strategic planning to continuing the company’s momentum \n and unlocking the value of our technology. My immediate priority is to \n secure additional funding for Bioasis to ensure that we have the \n necessary resources to continue to execute on our ongoing development \n and partnering initiatives.”\n \n \n The Board would like to thank Dr. Mark Day for his contributions to the \n company over the past few years and wish him well in his future \n endeavours.\n \n \n Bioasis also announces that it has recently granted stock options to \n acquire a total of 1,616,000 common shares at exercise prices ranging \n from $0.445 - $0.55 per share to executives of the company, with t...